The prescribing information from the FDA for midostaurin described that the midostaurin-induced cardiac AEs mainly included hypertension and pericardial effusion according to the safety evaluation of midostaurin-treated patients with FLT3 mutated AML at a dose of 50 mg twice daily (U.S. Food and Drug Administration, 2017e). The gene discussed is FLT3; the disease is acute myeloid leukemia.